Current partner codePEPTIDESDE
PeptideStat
Menu

Vendors

Compare pricesVendor directoryVendor reviewsDiscount codesLab tests & COAs

Research

ResearchDatabaseClinical trials

Tools

All calculatorsReconstitutionAccumulationUnit converterPeptide chemistry
NCT07282600·Phase 3·INTERVENTIONAL

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

EloralintideWeight lossType 2 diabetesRecruiting

Status

Recruiting

Phase

Phase 3

Enrollment

1,035

Locations

159

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.

Interventions

Treatment arms and agents.

DRUG

Eloralintide

Administered SC

DRUG

Placebo

Administered SC

Timeline

From registration to results.

  1. First posted

    Dec 15, 2025

  2. Study start

    Dec 15, 2025

  3. Primary completion

    Jan 2028

  4. Study completion

    Feb 2028

  5. Results posted

    Not reported

  6. Registry updated

    Jul 17, 2026

Outcomes

What the study measures.

Primary outcomes

Percent Change from Baseline in Body Weight

Time frame · Baseline, Week 64

Secondary outcomes

Percent Change from Baseline in Total Body Fat Mass

Time frame · Baseline, Week 64

Change from Baseline in Waist Circumference

Time frame · Baseline, Week 64

Change from Baseline in Hemoglobin A1c (HbA1c)

Time frame · Baseline, Week 64

Percent Change in Baseline in Triglycerides

Time frame · Baseline, Week 64

Change from Baseline in Systolic Blood Pressure

Time frame · Baseline, Week 64

Change from Baseline in Body Mass Index (BMI)

Time frame · Baseline, Week 64

Percent Change from Baseline in High Sensitivity C-Reactive Protein (hsCRP)

Time frame · Baseline, Week 64

Percent Change from Baseline in Fasting Insulin

Time frame · Baseline, Week 64

Change in Medication Use

Time frame · Baseline through Week 64

Change from Baseline in Estimated Glomerular Filtration Rate (eGFR)

Time frame · Baseline, Week 64

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
Not reported
Sex
ALL
Healthy volunteers
No

Inclusion Criteria: * Have type 2 diabetes * Are on stable treatment for type 2 diabetes for at least 90 days prior to screening * Have a BMI ≥ 27 kg/m2 * Have a stable body weight (\<5% body weight change) for 90 days prior to screening Exclusion Criteria: * Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening) * Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening) * Have type 1 diabetes * Have taken any of the following antihyperglycemic medications within 90 days before screening: * amylin analogs * glucagon-like peptide-1 (GLP-1) receptor agonists * glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GIP/GLP) receptor agonists, or * insulin * Have had within 90 days prior to screening: * heart attack * stroke * coronary artery revascularization * unstable angina, or * hospitalization due to congestive heart failure * Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure * Have taken medications or alternative remedies intended for weight loss within 90 days of screening

Study locations

159 registered sites.

Argentina · China · Czechia · Germany · India · Japan · Mexico · Poland · Puerto Rico · Slovakia · South Korea · Spain · Taiwan · United States. Showing up to 24 locations stored in the fast local snapshot.

Birmingham Clinical Research

Birmingham, Alabama, United States

Cullman Clinical Trials

Cullman, Alabama, United States

Tucson Clinical Research Institute

Tucson, Arizona, United States

San Fernando Valley Health Institute

Canoga Park, California, United States

AMCR Institute

Escondido, California, United States

NorCal Medical Research, Inc

Greenbrae, California, United States

Ark Clinical Research

Long Beach, California, United States

Pacific Clinical Studies

Los Alamitos, California, United States

Inglewood Clinical

Los Angeles, California, United States

Care Access - Santa Clarita

Santa Clarita, California, United States

Encompass Clinical Research

Spring Valley, California, United States

Diablo Clinical Research, Inc.

Walnut Creek, California, United States

Care Access - Aurora

Aurora, Colorado, United States

New England Research Associates, LLC

Bridgeport, Connecticut, United States

CMR of Greater New Haven, LLC

Hamden, Connecticut, United States

Arrow Clinical Trials

Daytona Beach, Florida, United States

Care Access - Delray Beach

Delray Beach, Florida, United States

Fleming Island Center for Clinical Research

Fleming Island, Florida, United States

Nature Coast Clinical Research - Inverness

Inverness, Florida, United States

Jacksonville Center for Clinical Research

Jacksonville, Florida, United States

Flourish Research Acquisition, LLC dba Flourish Research - North Miami

Miami, Florida, United States

New Horizon Research Center

Miami, Florida, United States

Adult Medicine of Lake County, Inc.

Mt. Dora, Florida, United States

American Research Centers of Florida

Pembroke Pines, Florida, United States

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

ClinicalTrials.gov ↗Search PubMed ↗Search FDA ↗Search EMA ↗

Related trials

More studies on Eloralintide.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.

TrialsEloralintide trial dashboard →